Key Points
- Director Srinivas Akkaraju bought 244,300 shares of Kalaris Therapeutics at an average price of $4.83, a transaction worth about $1.18 million. After the purchase, he owned 2.22 million shares, increasing his stake by 12.34%.
- Kalaris Therapeutics recently reported better-than-expected quarterly earnings, posting EPS of -$0.46 versus the -$0.52 consensus estimate. Analysts currently expect the company to post -$2.09 EPS for the full fiscal year.
- Wall Street sentiment remains mixed but generally constructive, with a Moderate Buy consensus and an average price target of $15.60. Institutional investors also hold a large portion of the stock, with 66.05% ownership.
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) Director Srinivas Akkaraju acquired 244,300 shares of the firm's stock in a transaction on Wednesday, May 20th. The shares were bought at an average cost of $4.83 per share, for a total transaction of $1,179,969.00. Following the completion of the acquisition, the director directly owned 2,224,147 shares of the company's stock, valued at approximately $10,742,630.01. This represents a 12.34% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Kalaris Therapeutics Price Performance
Shares of KLRS opened at $4.92 on Friday. The company has a market capitalization of $117.05 million, a P/E ratio of -2.29 and a beta of 0.15. Kalaris Therapeutics Inc. has a one year low of $2.14 and a one year high of $11.88. The business's 50 day simple moving average is $6.01 and its 200-day simple moving average is $7.50.
Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.06. On average, sell-side analysts anticipate that Kalaris Therapeutics Inc. will post -2.09 EPS for the current fiscal year.
Analysts Set New Price Targets
Several research firms recently weighed in on KLRS. Wall Street Zen cut shares of Kalaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. Citigroup restated an "outperform" rating on shares of Kalaris Therapeutics in a research report on Wednesday, May 13th. Citizens Jmp reduced their target price on shares of Kalaris Therapeutics from $26.00 to $25.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 13th. Morgan Stanley initiated coverage on shares of Kalaris Therapeutics in a research note on Thursday, April 16th. They set an "overweight" rating and a $14.00 price objective for the company. Finally, Wedbush started coverage on shares of Kalaris Therapeutics in a research note on Thursday, May 14th. They set an "outperform" rating and a $17.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Kalaris Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $15.60.
Get Our Latest Stock Analysis on KLRS
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. RTW Investments LP acquired a new stake in shares of Kalaris Therapeutics during the 4th quarter worth approximately $10,972,000. Paradigm Biocapital Advisors LP acquired a new stake in Kalaris Therapeutics in the fourth quarter valued at approximately $5,908,000. Alyeska Investment Group L.P. acquired a new stake in Kalaris Therapeutics in the fourth quarter valued at approximately $3,402,000. Ikarian Capital LLC bought a new stake in shares of Kalaris Therapeutics in the fourth quarter worth $3,038,000. Finally, Woodline Partners LP acquired a new stake in Kalaris Therapeutics in the third quarter valued at $1,394,000. 66.05% of the stock is owned by institutional investors.
Kalaris Therapeutics Company Profile
(
Get Free Report)
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
